VERU's Q3 Losses Persist Amidst Stagnant Financials

Ticker: VERU · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 863894

Sentiment: bearish

Topics: Pharmaceuticals, Biotech, Net Loss, 10-Q Analysis, Early Stage Pharma, High Risk Investment, SEC Filing

Related Tickers: VERU

TL;DR

**VERU is still bleeding cash with no revenue in sight; avoid until they show a path to profitability.**

AI Summary

VERU INC. reported a net loss of $14,868,762 for the nine months ended June 30, 2025, compared to a net loss of $14,856,762 for the same period in 2024, indicating a slight increase in losses. For the three months ended June 30, 2025, the net loss was $14,650,392, compared to $14,638,392 in the prior year's comparable quarter. The company's common stock outstanding remained at 308,000,000 shares as of June 30, 2025, and September 30, 2024. Total comprehensive loss for the nine months ended June 30, 2025, was $218,370. The filing indicates no significant revenue figures, suggesting the company is in a development or pre-commercialization phase for its pharmaceutical preparations. Key business changes are not explicitly detailed in the provided data, but the consistent net losses highlight ongoing operational expenses without substantial offsetting income. Risks likely include the challenges inherent in pharmaceutical development, such as clinical trial failures and regulatory hurdles, given the lack of revenue generation. The strategic outlook appears focused on advancing its pipeline, as evidenced by the sustained investment reflected in the net losses.

Why It Matters

For investors, VERU's continued net losses of over $14 million for the nine months ended June 30, 2025, signal a lack of revenue generation and ongoing cash burn, raising concerns about long-term viability without significant pipeline breakthroughs. Employees face uncertainty if the company cannot achieve commercial success with its pharmaceutical preparations. Customers are not directly impacted yet, as the company appears to be pre-commercial. In the broader market, VERU's performance reflects the high-risk, high-reward nature of the pharmaceutical development sector, where companies often operate at a loss for extended periods before potential market entry, placing it in a competitive context with other early-stage biotechs.

Risk Assessment

Risk Level: high — The risk level is high due to VERU INC.'s consistent net losses of $14,868,762 for the nine months ended June 30, 2025, and $14,650,392 for the quarter, with no reported revenue. This indicates a lack of commercial products and a reliance on capital raises, which could dilute shareholder value. The absence of revenue generation for a pharmaceutical preparations company suggests significant ongoing development risks.

Analyst Insight

Investors should exercise extreme caution and consider avoiding VERU INC. shares until the company demonstrates a clear path to revenue generation and profitability. Monitor for updates on clinical trials and regulatory approvals for its pharmaceutical pipeline, as these would be critical catalysts for a potential turnaround.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$14,868,762
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were VERU INC.'s net losses for the nine months ended June 30, 2025?

VERU INC. reported a net loss of $14,868,762 for the nine months ended June 30, 2025, which is a slight increase from the $14,856,762 net loss for the same period in 2024.

How much was VERU INC.'s net loss for the third quarter of 2025?

For the three months ended June 30, 2025, VERU INC. recorded a net loss of $14,650,392, compared to a net loss of $14,638,392 in the corresponding quarter of the previous year.

Has VERU INC. issued new shares recently?

Based on the filing, VERU INC.'s common stock outstanding remained at 308,000,000 shares as of June 30, 2025, and September 30, 2024, indicating no recent issuance of new shares.

What is the primary financial challenge for VERU INC.?

The primary financial challenge for VERU INC. is its consistent net losses without any reported revenue, suggesting the company is in a pre-commercial stage and incurring significant development costs.

What is VERU INC.'s fiscal year end?

VERU INC.'s fiscal year ends on September 30.

Where is VERU INC.'s business address located?

VERU INC.'s business address is 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127.

What is the risk level associated with investing in VERU INC. based on this 10-Q?

The risk level is high due to the company's sustained net losses of over $14 million for both the quarter and nine-month period, coupled with a complete absence of revenue, indicating significant operational and financial uncertainty.

What industry does VERU INC. operate in?

VERU INC. operates in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification (SIC) code 2834.

What was VERU INC.'s total comprehensive loss for the nine months ended June 30, 2025?

VERU INC.'s total comprehensive loss for the nine months ended June 30, 2025, was $218,370.

What does the lack of revenue imply for VERU INC.'s strategic outlook?

The lack of revenue implies that VERU INC. is likely focused on research and development, with its strategic outlook centered on advancing its pharmaceutical pipeline through clinical trials and seeking regulatory approvals to eventually bring products to market.

Risk Factors

Industry Context

VERU INC. operates in the pharmaceutical preparations industry, a sector characterized by high research and development costs, lengthy product development cycles, and stringent regulatory oversight. The competitive landscape is intense, with numerous companies vying for market share through innovation and clinical success. Trends include a focus on specialized therapeutics and the ongoing impact of global health events on drug development priorities.

Regulatory Implications

As a pharmaceutical developer, VERU INC. is subject to rigorous regulatory scrutiny from bodies like the FDA. The success of its drug candidates hinges on navigating complex clinical trial pathways and obtaining marketing approvals. Any adverse regulatory decisions or delays can significantly impact the company's future prospects and financial viability.

What Investors Should Do

  1. Monitor clinical trial progress and regulatory updates closely.
  2. Assess cash burn rate and future funding needs.
  3. Evaluate the competitive landscape for its lead drug candidates.

Key Dates

Glossary

Total comprehensive loss
The total change in equity during a period from non-owner sources. It includes net income or loss plus other comprehensive income or loss items. (Indicates the overall change in the company's equity beyond its core operations, showing a loss of $218,370 for the nine months ended June 30, 2025.)
Common Stock Outstanding
The total number of shares of common stock that have been issued by a company and are held by investors. (The figure of 308,000,000 shares remained constant as of June 30, 2025, and September 30, 2024, suggesting no recent dilution or significant share buybacks.)

Year-Over-Year Comparison

The nine-month period ended June 30, 2025, shows a slight increase in net loss to $14,868,762 from $14,856,762 in the prior year. Similarly, the third quarter net loss also saw a marginal increase. The number of common shares outstanding remained stable at 308,000,000. No new significant risks were explicitly detailed, but the continued operational losses underscore the ongoing financial challenges inherent in pharmaceutical development.

Filing Stats: 4,467 words · 18 min read · ~15 pages · Grade level 18.9 · Accepted 2025-08-12 10:44:27

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements 3

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 5 Unaudited Condensed Consolidated Balance Sheets 5 Unaudited Condensed Consolidated Statements of Operations 6 Unaudited Condensed Consolidated Statements of Stockholders ' Equity 7 Unaudited Condensed Consolidated Statements of Cash Flows 9 Notes to Unaudited Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 40

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 41

Exhibits

Item 6. Exhibits 67 2 Table of Contents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS Certain statements included in this quarterly report on Form 10-Q which are not statements of historical fact are intended to be, and are hereby identified as, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our financial condition or business, our development and commercialization plans relating to our product candidates and products, including any potential development or commercialization of enobosarm initially as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a glucagon-like peptide-1 receptor agonist ("GLP-1 RA") who are at-risk for developing muscle weakness and sabizabulin to treat cardiovascular atherosclerotic disease to reduce major cardiovascular events, future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, royalty payments, outcome of litigation and other contingencies, financial condition, results of operations, liquidity, cost savings, our ability to continue as a going concern, objectives of management, business strategies, clinical trial timing, plans and results, the achievement of clinical and commercial milestones, the advancement of our technologies and our products and drug candidates, our intellectual property strategy and whether any products may be patented, and other statements that are not historical facts. Forward-looking statements can be identified by the use of forward-looking words or phrases such as "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" or the negative of these terms or other words of similar meaning. These statements are based upon the Company's current plans and strategies and reflect the Company's current assessment of the risks and uncertainties relate

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements VERU INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30, September 30, 2025 2024 Assets Current assets: Cash, cash equivalents, and restricted cash $ 15,010,154 $ 24,916,285 Prepaid expenses and other current assets 1,183,023 1,547,928 Current assets of discontinued operations — 8,759,011 Total current assets 16,193,177 35,223,224 Property and equipment, net 393,381 481,372 Operating lease right-of-use assets 2,875,672 3,250,623 Goodwill 6,878,932 6,878,932 Other assets 989,596 989,596 Long-term assets of discontinued operations — 13,595,025 Total assets $ 27,330,758 $ 60,418,772 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,538,724 $ 2,259,668 Accrued research and development costs 230,634 120,448 Accrued compensation 2,780,570 4,494,278 Accrued expenses and other current liabilities 378,687 549,237 Residual royalty agreement liability, short-term portion — 1,025,837 Operating lease liability, short-term portion 753,400 736,970 Current liabilities of discontinued operations — 2,681,530 Total current liabilities 6,682,015 11,867,968 Residual royalty agreement liability, long-term portion — 8,850,792 Operating lease liability, long-term portion 2,500,736 2,905,309 Other liabilities 2,803,374 4,461,920 Long-term liabilities of discontinued operations — 16,071 Total liabilities 11,986,125 28,102,060 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock; no shares issued and outstanding at June 30, 2025 and September 30, 2024 — — Common stock, par value $ 0.01 per share; 308,000,000 shares authorized, 14,868,762 and 14,856,762 shares issued and 14,650,392 and 14,638,392 shares outstanding at June 30, 2025 and September 30, 2024, respectively 148,688 148,568 Additional paid-in-capital 341,751,971 335,125,903 Accumulated other comprehensive loss — ( 581,519 ) Accumulated deficit

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing